FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 601 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For... December 9, 2019 6 of the biggest good news cancer stories of 2021 December 15, 2021 Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer July 6, 2021 Phytochemicals and Antioxidants December 11, 2020 Load more HOT NEWS Woman Perfectly Breaks Down Grief Using ‘Ball In The Box’ Analogy... Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance
